Cart
sales@molnova.com
PTUPB
CAS No. 1287761-01-6
PTUPB( —— )
Catalog No. M11173 CAS No. 1287761-01-6
PTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 205 | In Stock |
|
| 5MG | 170 | In Stock |
|
| 10MG | 275 | In Stock |
|
| 25MG | 511 | In Stock |
|
| 50MG | 799 | In Stock |
|
| 100MG | 1190 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePTUPB
-
NoteResearch use only, not for human use.
-
Brief DescriptionPTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM.
-
DescriptionPTUPB is a novel dual acting COX-2/sEH inhibitor with IC50 of 1.26 uM/0.9 nM,does not inhibits COX-1 (IC50>100 uM); reduces kidney injury parameters, decreases inflammatory and oxidative stress markers in ZDF rats; exhibits more effective than the same dose of either COX-2 inhibitor (celecoxib) or sEH inhibitor (t-AUCB) alone, shows in vivo antiallodynic activity in vivo; also suppresses glioblastoma growth by targeting EGFR and hyaluronan mediated motility receptor, potentiates the antitumor efficacy of cisplatin.
-
In VitroCell Viability Assay Cell Line:Multiple cancer cell lines: PC-3 cells, Met-1, H-1, A375, and transformed endothelial cell line (bEnd.3)Concentration:10 μM, 15 μM, and 20 μM Incubation Time:72 hours Result:Inhibited HUVEC proliferation after 3 days.Cell Cycle Analysis Cell Line:HUVECs Concentration:10 μM, 15 μM, and 20 μM Incubation Time:72 hours Result:Induced cell cycle arrest at the G0/1 phase.
-
In VivoAnimal Model:C57BL/6 mice with?LLC cells Dosage:30 mg/kg; 4 weeks Administration:Subcutaneous injection via Alzet osmotic minipumps; once daily; 4 weeks Result:Inhibited LLC tumor growth and metastasis.Animal Model:High-fat diet (HFD)-induced obeseadult male C57BL/6 mice Dosage:5 mg/kg; 12 weeks Administration:Subcutaneous injection; once daily; 12 weeks Result:Arrested fibrotic progression and ameliorated high-fat diet-induced non-alcoholic fatty liver disease.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1287761-01-6
-
Formula Weight543.565
-
Molecular FormulaC26H24F3N5O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (183.97 mM)
-
SMILES——
-
Chemical Name4-(5-phenyl-3-{3-[3-(4-trifluoromethylphenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hye Khan MA, et al. Prostaglandins Other Lipid Mediat. 2016 Sep;125:40-7.
2. Li J, et al. Oncotarget. 2017 Sep 15;8(50):87353-87363.
3. Wang F, et al. Mol Cancer Ther. 2018 Feb;17(2):474-483.
4. Hwang SH, et al. J Med Chem. 2011 Apr 28;54(8):3037-50.
molnova catalog
related products
-
Agnuside
Agnuside inhibits COX-2 (IC50: 0.026 mg/ml) but exhibits less than 10% inhibition of COX-1 at this concentration. It also inhibits 46.3 66.8 and 82.1% of P-glycoprotein (P-gp) ATPase activity at concentrations of 5 25 and 100 μM respectively.
-
Indobufen
Indobufen is an inhibitor of platelet aggregation and is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes.
-
Sasapyrine
Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins.
